College ter Beoordeling van Geneesmiddelen / Medicines Evaluation Board

Graadt van Roggenweg 500
3531 AH Utrecht
The Netherlands

DECENTRALISED PROCEDURE

PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT

Pimotab 1.25 mg chewable tablets for dogs
Pimotab 2.5 mg chewable tablets for dogs
Pimotab 5 mg chewable tablets for dogs
Pimotab 10 mg chewable tablets for dogs
Pimotab 15 mg chewable tablets for dogs

NL/V/0297/001-005/DC

Created: 29 July 2021
Updated: 15 July 2022

MODULE 1

PRODUCT SUMMARY

EU Procedure number	NL/V/0297/001-005/DC
Name, strength and pharmaceutical form	Pimotab 1.25 mg chewable tablets for dogs Pimotab 2.5 mg chewable tablets for dogs Pimotab 5 mg chewable tablets for dogs Pimotab 10 mg chewable tablets for dogs Pimotab 15 mg chewable tablets for dogs
Applicant	CP-Pharma Handelsgesellschaft mbH Ostlandring 13 31303 Burgdorf Germany
Active substance(s)	Pimobendan
ATC Vetcode	QC01CE90
Target species	Dogs
Indication for use	For the treatment of canine congestive heart failure originating from dilated cardiomyopathy or valvular insufficiency (mitral and/or tricuspid valve regurgitation).

Pimotab	NL/V/0297/001-005/DC
CP-Pharma Handelsgesellschaft mbH	DCP
	Publicly available assessment report

MODULE 2

The Summary of Product Characteristics (SPC) for this product is available on the Heads of Veterinary Medicines Agencies website (http://www.HMA.eu).

MODULE 3

PUBLIC ASSESSMENT REPORT

Legal basis of original application	Hybrid application in accordance with Article 13(3) of Directive 2001/82/EC as amended.
Date of completion of the original decentralised procedure	18 December 2019
Date of completion of the Repeat Use Procedure	16 November 2020
Date product first authorised in the Reference Member State (MRP only)	Not applicable
Concerned Member States for original procedure (DCP)	AT, BE, DE, DK, ES, FI, HU, IE, IT PL, SE, UK (NI)
Concerned Member States for Repeat Use Procedure	EE, FR, LT, LV

I. SCIENTIFIC OVERVIEW

The product is produced and controlled using validated methods and tests, which ensure the consistency of the product released on the market.
It has been shown that the product can be safely used in the target species; the slight reactions observed are indicated in the SPC.
The product is safe for the user and for the environment, when used as recommended. Suitable warnings and precautions are indicated in the SPC.
The efficacy of the product was demonstrated according to the claims made in the SPC.
The overall risk/benefit analysis is in favour of granting a marketing authorisation.

The legal base for this application, a hybrid application, is based on a change in strength for all tablet applications except for the 2.5 mg tablet. The reference product for this procedure is Vetmedin 2.5 mg Kapseln für Hunde, with marketing authorisation number DE 400150.00.00, authorized in Germany on 15 April 1999. During the original Decentralised Procedure, Vetmedin 5 mg was also referenced, to substantiate a more extensive indication. However, these indications were later withdrawn (see Module 4), and therefore Vetmedin 5 mg was no longer referenced during the subsequent Repeat Use Procedure.

Pimotab	NL/V/0297/001-005/DC
CP-Pharma Handelsgesellschaft mbH	DCP
	Publicly available assessment report

II. QUALITY ASPECTS

A. Qualitative and quantitative particulars

The tablets contain 1.25 mg, 2.5 mg, 5 mg 10 mg or 15 mg Pimobendan and the following excipients: citric acid anhydrous, povidone K25, lactose monohydrate, cellulose microcrystalline, croscarmellose sodium, chicken flavour, yeast (dried), silica colloidal hydrated and magnesium stearate.

The tablet is cross scored and meant to be broken in halves or quarters.

The tablets are packed in AL-OPA/AL/PVC blisters.

The product is an established pharmaceutical form and its development is adequately described in accordance with the relevant European guidelines.

For the generic 2.5 mg tablet strength a bioequivalence study is performed. According to the comparative dissolution profiles, a biowaiver can be granted for the 1.25 mg, 5 mg, 10 mg and 15 mg tablet strengths.

B. Method of Preparation of the Product

The product is manufactured fully in accordance with the principles of good manufacturing practice from a licensed manufacturing site.

The product is manufactured using conventional manufacturing techniques. Suitable pre-approval validation results on two common blend validation batches divided into two batches of each strength of Pimobendan chewable tablets, resulting in 10 sub batches, have been provided.

The tests performed during production are described.

C. Control of Starting Materials

The active substance Pimobendan is an established active substance described in the European Pharmacopoeia. The active substance is manufactured in accordance with the principles of good manufacturing practice.

The active substance specification is considered adequate to control the quality of the material. Batch analytical data demonstrating compliance with this specification have been provided.

The in-house monographs and additional information in regard to the flavouring agents is acceptable. All other excipients are in conformity with the Ph.Eur. requirements.

None of the starting materials used are affected by the Note for Guidance on TSE/BSE.

D. Control on intermediate products

Not applicable.

E. Control Tests on the Finished Product

The finished product specification controls the relevant parameters for the pharmaceutical form.

All tests in the release specification, and their limits, have been justified and are considered appropriate to adequately control the quality of the product.

The dissolution method has been adequately described and the parameters are justified. The method is discriminatory and has been adequately validated. The proposed method and dissolution limit is in line with the Reflection paper on dissolution

Satisfactory validation data for the analytical methods have been provided.

Batch analytical data from the proposed production site has been provided demonstrating compliance with the specification.

F. Stability

The retest period for pimobendan is stated on the CEP.

Stability data on the finished product has been provided in accordance with applicable VICH guidelines.

According to the 36 months stability results provided the claimed shelf life of 3 years can be granted for all tablet strength.
An in-use shelf life of 3 days after first use (divided tablets), without special storage restrictions can be granted.

G. Other Information

Not applicable.

III. SAFETY AND RESIDUES ASSESSMENT (PHARMACO-TOXICOLOGICAL)

As this is a generic application according to Article 13, and bioequivalence with the reference product has been demonstrated, results of toxicological and pharmacological tests are not required. The toxicological and pharmacological aspects of this product are identical to the reference product.

Warnings and precautions as listed on the product literature are adequate to ensure safety of the product to users and the environment.

User Safety

The applicant has provided a user safety assessment in compliance with the relevant guideline. The following sentences are added to the SPC to mitigate risk of exposure:

“This product may cause tachycardia, orthostatic hypotension, flushing of the face and headaches.

To avoid accidental ingestion, especially by a child, unused tablet parts should be placed back into the blister and carton and carefully kept away from children. Part used tablets should be used at the time of the next dose. In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.

Wash hands after use.”

Warnings and precautions as listed on the product literature are adequate to ensure safety to users of the product.

Pimotab	NL/V/0297/001-005/DC
CP-Pharma Handelsgesellschaft mbH	DCP
	Publicly available assessment report

Environmental Risk Assessment

A Phase I environmental risk assessment (ERA) was provided according to the CVMP/VICH guidelines.

Phase I:

The environmental risk assessment can stop in Phase I and no Phase II assessment is required because the veterinary medicinal product will only be used in non-food animals.

IV. CLINICAL ASSESSMENT (EFFICACY)

As this is a generic application according to Article 13, and bioequivalence with a reference product has been demonstrated, efficacy studies are not required. A biowaiver for the additional strengths was granted. The efficacy claims for this product are equivalent to those of the reference product.

V . OVERALL CONCLUSION AND BENEFIT– RISK ASSESSMENT

The data submitted in the dossier demonstrate that when the product is used in accordance with the Summary of Product Characteristics, the risk benefit profile for the target species is favourable and the quality and safety of the product for humans and the environment is acceptable.

MODULE 4

POST-AUTHORISATION ASSESSMENTS

The SPC and package leaflet may be updated to include new information on the quality, safety and efficacy of the veterinary medicinal product. The current SPC is available on the Heads of Veterinary Medicines Agencies website (www.HMA.eu).

This section contains information on significant changes which have been made after the original procedure which are important for the quality, safety or efficacy of the product.

Summary of change (procedure number)	**Section updated**	**Approval date**
Deletion of therapeutic indications (NL/V/0297/IB/001/G)	SPC/PL updated Module 3.1 updated	16 July 2020
Repeat Use Procedure (NL/V/0297/001-005/E/001)	Module 3 (table) updated	16 November 2020
Introduction of a new manufacturer for pimobendan (NL/V/0297/001-005/II/002)	NA	13 July 2022